Molecular genomic landscape of myeloid neoplasms in elderly patients

王婷,晁红颖,陈涛,杨建和,周峰,章艳,张日,王谦

DOI: https://doi.org/10.3760/cma.j.issn.0254-9026.2020.02.014

2020-01-01

Abstract:Objective:To explore the molecular genetics of myeloid neoplasms in elderly patients.Methods:High-throughput DNA sequencing was performed to detect 49 target gene mutations in 26 patients with acute myeloid leukemia(AML)and 51 patients with myelodysplastic syndrome(MDS). Genomic DNA-PCR and Sanger sequencing were used to detect the mutations of CALR gene exon 9, NMP1 gene exon 12, FLT3-ITD and the two functional domains, TAD and BZIP, in CEBPA.Results:(1)Of the 77 patients enrolled, the overall incidence of gene mutations was 91.0%(71/77), with an average of 2 mutations per patient and an incidence of 42.9% for the coexistence of 3 or more gene mutations(33/77), and the most common genetic mutations were NPM1, U2AF1, RUNX1, TET2, ASXL1, TP53, DNMT3A, IDH2, BCOR, and FLT3-ITD, and the incidence of other genetic mutations was<10%.(2)The incidence of double gene mutations in the AML group was significantly higher than that in the MDS group, and the incidence of≥3 gene mutations in the MDS group was higher than that in the AML group( P<0.05). The AML group was associated with significantly higher incidences of NPM1, FLT3-ITD, and CEBPA double mutations and lower incidences of BCOR and ASXL1 mutations than those in the MDS group(all P<0.05). Functional classification showed that tyrosine kinase receptor gene mutations mainly occurred in the AML group( P=0.004), while chromatin modified gene mutations mainly occurred in the MDS group( P=0.007). (3)Fifty-one cases with MDS were followed up and 9 cases developed leukemia transformation with an average transformation time of 6.5 months during the period, and the conversion rate of patients with RUNX1 and U2AF1 mutations was 44.4%, which was higher than that of other gene mutations. Conclusions:Elderly patients with myeloid neoplasms have unique gene mutation profiles.The types and frequencies of common myeloid tumor gene mutations are different in AML and MDS, and some gene mutations in patients with MDS are related to leukemia transformation.